British drugmaker GSK has settled lawsuits that accused Moderna’s COVID-19 vaccines Spikev
ax and mNEXSPIKE and RSV shot mResvia of infringing its patents, the companies said on Oct. 6.
Moderna said in a press release that it settled GSK’s patent litigation in the US and Europe on O
ctober 28 and that the companies “granted patent cross-licenses in the field of infectious disease and are not obligated to make payments of any kind in connection with such licenses.”
A GSK spokesperson said the company was “pleased to have reached a resolution that provides clarity for both companies and enables continued focus on advancing innovation for patients.”
The companies asked a Delaware federal court on Oct. 6 to dismiss GSK’s US infringement claims with prejudice, which means they cannot be refiled.
GSK sued Moderna in 2024 over lipid nanoparticle technology used in the vaccines to tran
sport fragile messenger RNA (mRNA) into the human body. GSK separately filed a similar lawsuit against Pfizer and BioNTech over their COVID-19 vaccine earlier that year, which is still ongoing.
Watch More Image Part 2 >>>
The lawsuits are part of a web of US court cases involving Pfizer, BioNTech and Moderna over patent royalties for technology used in their COVID vaccines, including one brought by Moderna against Pfizer in 2022
Root Inc. reported third quarter 2026 net income of $14.4 million, reversing a loss of $5.4 million over the same period a year ago.
For Q3 the combined ratio came in at 97.2 compared with 102.1 a year ago during the same time.
In a letter to shareholders, Root Inc, the parent of insurtech Root Insurance, said competition “intensified” in the personal auto insurance marketplace during the quarter.
Alex Timm, co-founder and CEO, said large insurers “increased marketing, broadened underwriting appetite, lowered average premiums, and competed more aggressively for growth.”
“We remained disciplined in direct and deployed capital only where expected returns met our thresholds,” he said, adding that in Q3, this meant passing on policy growth in the direct channel when returns did not meet Root’s standards.
Still, Root said its partnership channel grew 19% in Q3 and represented 52% of new writings compared with 44% last year in Q3. During the quarter, Root renewed its relationship with Carvana through August 2028 and launched a pilot with Hyundai.
“The renewal demonstrates the value of embedded insurance to customers at scale,” Timm wrote. “Vehicle buyers should not have to leave a high-intent purchase to complete a separate insurance process.”
With Root’s expansion to New Jersey in July and Wyoming last month, the insurer is now in 38 states.
Root said it completed development its latest pricing model and began deploying it in the fourth quarter, with the goal of a system that “operates end to end through AI and automation.”





























